Search clinical trials for: Placebo to Tofacitinib

Total 60290 results

Gilead Sciences

Withdrawn

Study to Evaluate Safety, Tolerability, and Efficacy of GS-5718 in Participants With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-modifying Antirheumatic Drug(s) (bDMARDs) Treatment

Rheumatoid Arthritis
Pfizer

Completed

Efficacy Study Of Tofacitinib In Pediatric JIA Population

Juvenile Idiopathic Arthritis

United States, Spain, Turkey, Canada, Australia, Israel, United Kingdom, Argentina, Brazil, Poland, Mexico, Belgium, Russian Federation, Ukraine
Stanford University
National Institutes of Health (NIH)

Recruiting

Janus Kinase Inhibition to Prevent Ventilator-induced Diaphragm Dysfunction

Diaphragm Injury

United States
Pfizer

Completed

Dose-Ranging Study Of Tofacitinib In Adults With Active Ankylosing Spondylitis

Ankylosing Spondylitis

Korea, Republic of, United States, Spain, Taiwan, Canada, Czech Republic, Poland, Hungary, Germany, Russian Federation
Pfizer

Completed

Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis

Plaque Psoriasis

United States
Nanfang Hospital of Southern Medical University
Jiangsu Simcere Pharmaceutical Co., Ltd.

Not yet recruiting

Iguratimod Combined With Tofacitinib in the Treatment of Rheumatoid Arthritis

Rheumatoid Arthritis
Hospital Israelita Albert Einstein
Pfizer

Completed

Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia

Covid19

Brazil
Pfizer

Completed

A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative Colitis (OCTAVE)

Ulcerative Colitis

Korea, Republic of, United States, United Kingdom, Australia, Austria, Denmark, Canada, Israel, Germany, Belgium, Taiwan, Latvia, Spain, Poland, New Zealand, Hungary, Netherlands, France, Estonia, Serbia, South Africa, Slovakia, Cro... and more
Theravance Biopharma

Completed

TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)

Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects

United States
Yale University

Terminated

Tofacitinib for Treatment of Moderate COVID-19 (I-TOMIC)

COVID-19 Pneumonia

United States
Pfizer

Completed

A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative Colitis (OCTAVE)

Ulcerative Colitis

United States, Spain, Canada, Israel, Australia, Germany, Serbia, Japan, Denmark, France, Hungary, Poland, United Kingdom, Belgium, New Zealand, Netherlands, Austria, Colombia, Croatia, Czech Republic, Estonia, Italy, Latvia, Romania, Russian... and more
Pfizer

Completed

Tofacitinib Ointment For Atopic Dermatitis (Atopic Eczema)

Dermatitis, Atopic

Canada
Pfizer

Completed

Efficacy And Safety Of Tofacitinib In Psoriatic Arthritis: Comparator Study (OPAL BROADEN)

Psoriatic Arthritis

United States, Canada, Spain, Germany, Australia, Hungary, Belgium, Mexico, Poland, Russian Federation, Taiwan, United Kingdom, Slovakia, Czechia, Bulgaria, France
Pfizer

Completed

Tofacitinib Bioequivalence Study Comparing Tablets And Capsules

Healthy

Singapore
University of Oxford
Medical Research Council; Wellcome Trust

Terminated

Tofacitinib in Depression (TIDE) (TIDE)

Depression | Inflammation

United Kingdom
Pfizer

Completed

A Study to Demonstrate the Equivalence of the Tofacitinib Oral Solution to the Tablet Formulation in Healthy Participants.

Healthy

United States
Pfizer

Completed

Tofacitinib Ointment For Chronic Plaque Psoriasis

Psoriasis | Psoriasis Vulgaris

United States, Canada, Denmark, Poland
Pfizer

Completed

A Phase 1 Study To Evaluate The Pharmacokinetics And Safety Of Three Modified Release And One Immediate Release Formulations Of Tofacitinib (CP-690,550) In Healthy Volunteers

Healthy

Singapore
CAGE Bio Inc.

Not yet recruiting

Tolerability and Effectiveness of CGB-500 Topical Ointment, 1% Tofacitinib, for the Treatment of Atopic Dermatitis

Atopic Dermatitis
Charite University, Berlin, Germany

Recruiting

Tofacitinib for Reduction of Spinal Inflammation in Patients With Psoriatic ArthritiS PresenTing With Axial InvOlvement (PASTOR)

Spondylitis | Psoriatic Arthritis | Sacroilitis

Germany
Aetion, Inc.

Active, not recruiting

Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments

COVID-19

United States
Pfizer

Completed

PK and Bioavailability Comparison of Tofacitinib Between a Modified Release and The Immediate Release Formulation

Healthy

China
Pfizer

Completed

A Study To Evaluate The Effect Of Food On The Behavior of Tofacitinib Modified Release 22 Milligram Tablets In Healthy Volunteers

Healthy

Belgium
Pfizer

Completed

A Safety, Efficacy And Pharmacokinetics Study Of Tofacitinib In Pediatric Patients With sJIA

Arthritis Juvenile Idiopathic

United States, Belgium, Spain, Canada, Mexico, Turkey, Israel, China, Slovakia, Hungary, India, Argentina, Brazil, Germany, South Africa, Poland, Ukraine, Italy, Costa Rica, Russian Federation, United Kingdom
Pfizer

Completed

Multiple Dose Escalation Study In Medically Stable Subjects With Psoriasis

Psoriasis | Immunomodulation

United States
Hansoh BioMedical R&D Company

Not yet recruiting

Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis

Psoriatic Arthritis
Norman B. Gaylis, MD

Completed

An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve Low Disease Activity (LDA) or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective

Rheumatoid Arthritis

United States
Yale University

Completed

Tofacitnib for the Treatment of Alopecia Areata and Variants

Alopecia Areata (AA) | Alopecia Totalis (AT) | Alopecia Universalis (AU)

United States
Shanghai Zhongshan Hospital

Completed

Effect of Tofacitinib in Treating ANCA-associated Vasculitis

Drug Use | ANCA Associated Vasculitis | JAK-STAT Pathway Deregulation

China
Washington University School of Medicine

Active, not recruiting

Tofacitinib for Inflammatory Eye Disease

Uveitis | Scleritis

United States
Jiangsu vcare pharmaceutical technology co., LTD

Recruiting

Efficacy and Safety Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.

Active Ankylosing Spondylitis

China
Huashan Hospital

Recruiting

Safety And Efficacy Of Tofacitinib In Patients With Refractory Myasthenia Gravis: A Pilot Study

Myasthenia Gravis, Generalized

China
Peking University People's Hospital

Recruiting

Clinical Characteristics and Mechanism Research of Inhibitors of Janus Kinase in the Idiopathic Inflammatory Myopathies

Idiopathic Inflammatory Myopathies

China
Yale University

Completed

Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants

Alopecia Areata | Alopecia Totalis | Alopecia Universalis

United States
Sichuan University

Unknown

Tofacitinib Combined With Chidamide in R/R ENKTCL

Extranodal NK/T-cell Lymphoma

China
National Institute of Dental and Craniofacial Research...

Recruiting

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Primary Sjogren's Syndrome

Sjogren's Syndrome

United States
Pfizer

Recruiting

Observational Study To Assess The Effectiveness and Treatment Adherence Of Tofacitinib of Ulcerative Colitis In Clinical Practice In Sweden (ODEN)

Ulcerative Colitis

Sweden
University of California, Los Angeles

Completed

Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients

Rheumatoid Arthritis

United States
Hanlim Pharm. Co., Ltd.

Completed

Study to Evaluate HL-TOF Tab. 5 mg Compared With XelJanz Tab. in Healthy Volunteers

Healthy Volunteers

Korea, Republic of
Pfizer

Recruiting

Korean Post-marketing Surveillance for Xeljanz XR (XRPMS)

Active Psoriatic Arthritis | Active Ankylosing Spondylitis | Active Moderate to Severe Rheumatoid Arthritis

Korea, Republic of
National Institute of Arthritis and Musculoskeletal...

Completed

Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus

United States
Pfizer

Completed

A Study To Evaluate The Effect Of CP-690,550 On Measures Of Kidney Function In Patients With Active Rheumatoid Arthritis

Arthritis, Rheumatoid

United States, Germany, Korea, Republic of, Spain, Czech Republic, Mexico, Poland, Russian Federation
Yanfeng Hou

Recruiting

Efficacy Study of Iguratimod Combined With Tofacitab in Patients With RF Positive/Negative Rheumatoid Arthritis

Rheumatoid Arthritis | Therapy

China
Pfizer

Completed

A Phase 1 Study To Evaluate The Pharmacokinetics (PK), Safety, And Bioavailability Of A Modified-Release (MR) Formulation Of Tofacitinib In Healthy Volunteers

Healthy

Singapore
University of Texas Southwestern Medical Center
Pfizer

Recruiting

Tofacitinib in Recurrent GBM Patients

Glioblastoma

United States
Pfizer

Recruiting

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

Ulcerative Colitis

United States, Israel, Poland, Canada, Japan, Belgium, Spain, Hungary, Finland, France, United Kingdom, Australia, Germany, Italy, Sweden, Netherlands, Slovakia
Jing Liang

Recruiting

Correlation Between the Change of Peripheral Lymphocyte Subsets and Clinically Amyopathic Dermatomyositis Combined With Rapidly Progressive Interstitial Lung Disease

Clinically Amyopathic Dermatomyisitis(CAMD)

China
Pfizer

Completed

A Study To Estimate The Amount Of CP-690,550 (Study Drug) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of CP-690,550 In Tablet Form

Healthy

Singapore
Charite University, Berlin, Germany
Pfizer

Not yet recruiting

ToFAcitinib in Early Active Axial SpondyloarThritis: (FASTLANE)

Axial Spondyloarthritis
Pfizer

Completed

A Study To Evaluate The Effect Of Food On The Behavior Of Tofacitinib Modified Release 11 Milligram Tablets In Healthy Western And Japanese Volunteers

Healthy

United States

Search clinical trials for: Placebo to Tofacitinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jamaica

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations